Understanding Alpha-1 Antitrypsin Deficiency (AATD)
At a Glance
Alpha-1 Antitrypsin Deficiency (AATD) is an inherited condition that reduces the body's protective proteins, leaving the lungs vulnerable to early-onset COPD and the liver prone to scarring. Early diagnosis, quitting smoking, and treatment can help protect your organs.
Receiving a diagnosis of Alpha-1 Antitrypsin Deficiency (AATD) often brings a mix of relief and concern. For many, this news comes after years of navigating unexplained respiratory or liver symptoms [1][2]. It is important to know that you are not alone; while once considered rare, AATD is one of the most common serious genetic conditions in the world [3][4].
What is Alpha-1?
Alpha-1 Antitrypsin Deficiency (AATD) is an inherited condition caused by mutations in the SERPINA1 gene [3]. This gene provides instructions for making the alpha-1 antitrypsin (AAT) protein, which is produced primarily in the liver [5][6].
In a healthy body, this protein travels through the bloodstream to the lungs. Its primary job is to act as a “protease inhibitor,” specifically neutralizing an enzyme called neutrophil elastase [7][8]. While neutrophil elastase helps fight infections, it can also digest healthy lung tissue if left unchecked [7][9]. In people with AATD, the protein is either not produced enough or is shaped incorrectly, leaving the lungs vulnerable [3][10].
How Common is It?
AATD affects approximately 1 in 1,600 to 1 in 2,000 live births in certain populations [1][4]. Despite this, it remains significantly underdiagnosed. Research suggests that up to 90% of individuals with the most severe form of the deficiency may not know they have it [1][4].
A Two-Part Disease Mechanism
AATD is unique because it affects the body through two distinct biological pathways:
- Lung Disease (Loss-of-Function): Because there isn’t enough functional AAT protein reaching the lungs, the “braking system” for inflammatory enzymes is lost [5][6]. This results in the gradual breakdown of the tiny air sacs in the lungs (alveoli), which can lead to early-onset emphysema or COPD (Chronic Obstructive Pulmonary Disease) [9][11][12].
- Liver Disease (Gain-of-Toxic-Function): In some types of AATD (most commonly the PiZZ genotype), the liver produces a “misfolded” version of the protein [13][14]. These malformed proteins get stuck inside the liver cells (hepatocytes) and form clumps [5][15]. This “gain of toxic function” can cause inflammation, scarring (cirrhosis), or liver failure over time [13][14]. In children, AATD liver involvement can also present early in infancy as prolonged neonatal jaundice [16].
Stabilizing Facts for the Newly Diagnosed
While a chronic diagnosis is life-changing, several key facts can provide a foundation for moving forward:
- Knowledge is Protective: Early detection is a powerful tool. Knowing you have AATD allows you to make specific lifestyle choices that can significantly slow the progression of the disease [2][1].
- Smoking Cessation is Vital: For those with lung involvement, the single most important action is avoiding tobacco smoke and environmental pollutants [17][10]. Smoking drastically accelerates lung damage in “Alphas” [18][19].
- Treatment Options Exist: Augmentation therapy—a weekly intravenous infusion of AAT protein from healthy donors—can help raise the protein levels in your blood and slow the loss of lung tissue [1][20][21].
- Family Testing: Since AATD is genetic, your diagnosis provides a “roadmap” for your relatives. Testing first-degree relatives (parents, siblings, and children) is the most efficient way to ensure they also receive the care they may need [22][23].
- Focus on the Future: Many people with AATD live full, active lives by managing their environment, staying physically active, and working closely with a specialist [24][25].
Navigating This Guide
To help you understand your diagnosis, manage your condition, and build your care team, we have created the following resources:
The Path to Diagnosis: Navigating the Long Road to Answers
Learn why Alpha-1 Antitrypsin Deficiency (AATD) is often misdiagnosed as asthma or COPD. Understand the diagnostic delay, early signs, and next steps.
Your Genetic Blueprint: Decoding PiZZ, PiSZ, and PiMZ
Learn how to read your Alpha-1 Antitrypsin Deficiency (AATD) lab report. Understand what PiZZ, PiSZ, and PiMZ genotypes mean for your lung and liver health.
Treatment Strategy: Protecting Your Lungs and Liver
Learn about treatment strategies for Alpha-1 Antitrypsin Deficiency (AATD). Explore augmentation therapy for lungs, liver monitoring, and lifestyle changes.
Building Your Care Team and Long-Term Monitoring
Learn how to build an Alpha-1 Antitrypsin Deficiency (AATD) care team. Discover essential long-term monitoring tests for your lungs, liver, and mental health.
Common questions in this guide
What causes Alpha-1 Antitrypsin Deficiency?
How does AATD affect the lungs and liver?
What is augmentation therapy for AATD?
Should my family members be tested for Alpha-1?
Why is quitting smoking so important if I have AATD?
Related questions
Get notified when new evidence is published on Alpha-1-antitrypsin deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (25)
- 1
Alpha-1 antitrypsin deficiency: outstanding questions and future directions.
Torres-Durán M, Lopez-Campos JL, Barrecheguren M, et al.
Orphanet journal of rare diseases 2018; (13(1)):114 doi:10.1186/s13023-018-0856-9.
PMID: 29996870 - 2
The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.
Lascano JE, Campos MA
Postgraduate medicine 2017; (129(8)):889-895 doi:10.1080/00325481.2017.1381539.
PMID: 28929906 - 3
Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.
Abreu N, Pereira VM, Pestana M, Jasmins L
GE Portuguese journal of gastroenterology 2023; (30(5)):327-335 doi:10.1159/000528809.
PMID: 37868641 - 4
Portuguese consensus document for the management of alpha-1-antitrypsin deficiency.
Lopes AP, Mineiro MA, Costa F, et al.
Pulmonology 2018; (24 Suppl 1()):1-21 doi:10.1016/j.pulmoe.2018.09.004.
PMID: 30473034 - 5
Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum.
Seixas S, Marques PI
The application of clinical genetics 2021; (14()):173-194 doi:10.2147/TACG.S257511.
PMID: 33790624 - 6
The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency.
McCarthy C, Reeves EP, McElvaney NG
Annals of the American Thoracic Society 2016; (13 Suppl 4()):S297-304 doi:10.1513/AnnalsATS.201509-634KV.
PMID: 27564664 - 7
Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein.
Lechowicz U, Rudzinski S, Jezela-Stanek A, et al.
International journal of molecular sciences 2020; (21(23)) doi:10.3390/ijms21239187.
PMID: 33276468 - 8
Alpha-1 antitrypsin in autoimmune diseases: Roles and therapeutic prospects.
Sun R, Xu Z, Zhu C, et al.
International immunopharmacology 2022; (110()):109001 doi:10.1016/j.intimp.2022.109001.
PMID: 35803133 - 9
Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.
McElvaney NG
Annals of the American Thoracic Society 2016; (13 Suppl 2()):S191-6 doi:10.1513/AnnalsATS.201504-245KV.
PMID: 27115956 - 10
Pulmonary manifestations of alpha 1 antitrypsin deficiency.
Mulkareddy V, Roman J
The American journal of the medical sciences 2024; (368(1)):1-8 doi:10.1016/j.amjms.2024.04.002.
PMID: 38599244 - 11
Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease.
Stiles KM, Sondhi D, Kaminsky SM, et al.
Chronic obstructive pulmonary diseases (Miami, Fla.) 2018; (5(4)):244-257 doi:10.15326/jcopdf.5.4.2017.0160.
PMID: 30723782 - 12
Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF, Miravitlles M
Respiratory research 2017; (18(1)):105 doi:10.1186/s12931-017-0574-1.
PMID: 28558837 - 13
The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease.
Khodayari N, Wang RL, Oshins R, et al.
International journal of molecular sciences 2021; (22(24)) doi:10.3390/ijms222413255.
PMID: 34948056 - 14
Erdj3 Has an Essential Role for Z Variant Alpha-1-Antitrypsin Degradation.
Khodayari N, Marek G, Lu Y, et al.
Journal of cellular biochemistry 2017; (118(10)):3090-3101 doi:10.1002/jcb.26069.
PMID: 28419579 - 15
Patient-Derived Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Disease Modeling and Therapeutic Discovery.
Kaserman JE, Wilson AA
Chronic obstructive pulmonary diseases (Miami, Fla.) 2018; (5(4)):258-266 doi:10.15326/jcopdf.5.4.2017.0179.
PMID: 30723783 - 16
Liver Involvement in Children with Alpha-1 Antitrypsin Deficiency: A Multicenter Study.
Cakir M, Sag E, Islek A, et al.
Pediatric gastroenterology, hepatology & nutrition 2020; (23(2)):146-153 doi:10.5223/pghn.2020.23.2.146.
PMID: 32206627 - 17
Recurrence of emphysema post-lung transplantation in a patient with alpha 1 antitrypsin deficiency (AATD).
Ataya A
Respiratory medicine case reports 2020; (31()):101309 doi:10.1016/j.rmcr.2020.101309.
PMID: 33304809 - 18
[Alpha 1-antitrypsin deficiency].
Mornex JF
Revue des maladies respiratoires 2022; (39(8)):698-707 doi:10.1016/j.rmr.2022.02.062.
PMID: 35715315 - 19
Cigarette smoke exposed airway epithelial cell-derived EVs promote pro-inflammatory macrophage activation in alpha-1 antitrypsin deficiency.
Khodayari N, Oshins R, Mehrad B, et al.
Respiratory research 2022; (23(1)):232 doi:10.1186/s12931-022-02161-z.
PMID: 36068572 - 20
Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.
Greulich T
COPD 2017; (14(sup1)):S8-S11 doi:10.1080/15412555.2017.1286166.
PMID: 28306355 - 21
Alpha-1 Antitrypsin Deficiency: Current Landscape of Detection, Management, and Treatment.
Mawani R, Pye A, Turner AM
Advances in therapy 2026; doi:10.1007/s12325-026-03496-5.
PMID: 41678135 - 22
The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.
Sandhaus RA, Turino G, Brantly ML, et al.
Chronic obstructive pulmonary diseases (Miami, Fla.) 2016; (3(3)):668-682 doi:10.15326/jcopdf.3.3.2015.0182.
PMID: 28848891 - 23
Detection of alpha-1 antitrypsin deficiency: the past, present and future.
Brantly M, Campos M, Davis AM, et al.
Orphanet journal of rare diseases 2020; (15(1)):96 doi:10.1186/s13023-020-01352-5.
PMID: 32306990 - 24
Alpha-1 antitripsyn deficiency and augmentation therapy in pregnancy: two case reports.
Annunziata A, Fiorentino G, Coppola A, et al.
Frontiers in medicine 2024; (11()):1479877 doi:10.3389/fmed.2024.1479877.
PMID: 39736979 - 25
Alpha 1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease patients: is systematic screening necessary?
da Costa CH, Noronha Filho AJ, Marques E Silva RMF, et al.
BMC research notes 2019; (12(1)):10 doi:10.1186/s13104-018-4043-9.
PMID: 30630519
This page provides an educational overview of Alpha-1 Antitrypsin Deficiency (AATD). It is for informational purposes only and does not replace professional medical advice from your pulmonologist, hepatologist, or genetic counselor.